SCHEDULE: Lynx1 Capital Management Discloses Precision BioSciences Stake
Joint Acquisition Statement (Schedule 13G)
Lynx1 Capital Management LP and Weston Nichols have jointly filed a Schedule 13G, reporting beneficial ownership of 5.4% of Precision BioSciences Inc. common stock.
Summary
- Lynx1 Capital Management LP, acting as the investment manager for Lynx1 Master Fund LP, and Weston Nichols have filed a joint Schedule 13G statement.
- This filing indicates beneficial ownership of 1,390,611 shares of Precision BioSciences Inc. common stock.
- This represents approximately 5.4% of the company's outstanding common stock.
- The filing date for this statement is July 20, 2026, with the event date requiring the filing being July 13, 2026.
- The reporting persons are Lynx1 Capital Management LP (a Delaware limited partnership) and Weston Nichols (a U.S. citizen).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership without additional strategic commentary or financial performance data.
Positives
- Lynx1 Capital Management LP and Weston Nichols have disclosed a significant stake, indicating confidence or strategic interest in Precision BioSciences Inc.
- The reporting persons collectively hold 5.4% of the company's outstanding common stock, which is a notable ownership percentage.
Risks
- The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures associated with Schedule 13G filings.
- Potential for increased scrutiny from the market or management regarding the intentions of Lynx1 Capital Management LP and Weston Nichols due to their ownership stake.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors or individuals. The disclosure by Lynx1 Capital Management LP and Weston Nichols suggests a significant, though likely passive, interest in Precision BioSciences Inc., a company operating in the biotechnology sector.
Stakeholder Impact
- Shareholders: May view the increased ownership stake as a sign of potential institutional interest or a precursor to future strategic moves, though the passive nature of the filing suggests no immediate impact on control.
- Management: May seek to understand the intentions of Lynx1 Capital Management LP and Weston Nichols, especially if their stake grows or if they engage more actively.
- Competitors: Will note the significant stake held by an investment manager in Precision BioSciences Inc.
Next Steps
- The reporting persons will be responsible for timely filing of any subsequent amendments to this Schedule 13G.
- Market participants will monitor future filings for any changes in beneficial ownership or strategic actions by Lynx1 Capital Management LP and Weston Nichols.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date Precision BioSciences Inc. filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026. |
| 04/30/2026 | Date as of which the aggregate of 25,802,247 shares of Common Stock were outstanding. |
| 07/13/2026 | Date of the event which requires the filing of this Schedule 13G statement. |
| 07/20/2026 | Date the joint acquisition statement (Schedule 13G) was signed and filed. |
Keywords
Schedule 13G, Lynx1 Capital Management LP, Weston Nichols, Precision BioSciences Inc., Beneficial Ownership, Common Stock, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.